CD8A and neoplasm: ACM derived from OGJ patients with early-stage tumours significantly decreased the frequency of effector memory CD8+ T cells compared with untreated cells (untrx: 27.88 ± 2.7 vs. early-stage: 19.05 ± 3.0%, p = 0.03) (Fig. 1B).